2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-161705
    Anti-apoptotic agent 1 2563616-64-6
    Anti-apoptotic agent 1 (Compound B4) exhibits neuroprotective activity and good pharmacokinetic properties. Anti-apoptotic agent 1 inhibits apoptosis, prevents stroke recurrence in photothrombotic rat model.
    Anti-apoptotic agent 1
  • HY-161725
    TFEB activator 3 3027413-48-2
    TFEB activator 3 (compound 45) exhibits TFEB activation and lysosome biogenesis capabilities. TFEB activator 3 has effect on TFEB nuclear translocation with 44% (10μM 3h) and 97 % (30 μM 3h). TFEB activator 3 plays an important role in Alzheimer’s disease (AD). TFEB activator 3 can pass blodd brain barrier.
    TFEB activator 3
  • HY-161772
    (S)-Gebr32a 3055162-32-5
    (S)-Gebr32a is a potent PDE4 inhibitor with IC50 values of 19.5, 2.1 µM for PDE4 cat; PDE4D3, respectively.
    (S)-Gebr32a
  • HY-161783
    HDAC6-IN-45 3048532-05-1
    HDAC6-IN-45 (Compound 15) is a selective inhibitor for HDAC6 with IC50 of 15.2 nM. HDAC6-IN-45 exhibits neurotrophic through the upregulation of GAP43 and Beta-3 tubulin markers. HDAC6-IN-45 activates the Nrf2 signaling pathway, reduces H2O2-induced ROS production, inhibits apoptosis in PC12, and exhibits neuroprotective efficacy in SCOP-induced zebrafish Alzheimer's Disease models. HDAC6-IN-45 exhibits antioxidant activity and good blood-brain barrier (BBB) permeability.
    HDAC6-IN-45
  • HY-161784
    GABAA receptor modulator-5 3021554-08-2
    GABAA receptor modulator-5 (Compound S28) is a modulator for (γ-aminobutyric acid)A receptor (GABAA receptor), with EC50 of 56 nM and 10 nM, for α1β2γ2 and α4β3δ subtype. GABAA receptor modulator-5 exhibits good pharmacokinetic characteristics in rats. GABAA receptor modulator-5 is slightly toxic toxicity in rats with a loss of rollover reflex (LORR) threshold dose of 23.3 μmol/kg, and exhibits potential ameliorating the postpartum depression.
    GABAA receptor modulator-5
  • HY-161842
    AChE-IN-67
    AChE-IN-67 (compound 8n) is a potent AChE inhibitor, with an IC50 of 0.033 μM. AChE-IN-67 exhibits activity similar to Donepezil (HY-14566). AChE-IN-67 exhibits high blood-brain barrier (BBB) permeability. AChE-IN-67 can be used for Alzheimer's disease research.
    AChE-IN-67
  • HY-161846
    Tyrosinase-IN-31 903206-81-5
    Tyrosinase-IN-31 (compound 2-06) is a central-targeting tyrosinase inhibitor (tyrosinase: monophenolase IC50=70.44 μM, diphenolase IC50=1.89 μM). Tyrosinase-IN-31 can inhibit the tyrosinase and melanogenesis. Tyrosinase-IN-31 can penetrate the BBB and enter the central nervous system (CNS). Tyrosinase-IN-31 shows neuroprotective effects and Parkinsonism behavior improving function.
    Tyrosinase-IN-31
  • HY-161873
    PW507 2573850-59-4
    PW507 is a potent, brain-penetrant and selective sigma 1 receptor (S1R) antagonist with a Ki of 7.5 nM for human S1R. PW507 displays a low binding affinity to S2R and hERG. PW507 can be used for the study of painful diabetic neuropathy (PDN).
    PW507
  • HY-161896
    Transcription factor-IN-1
    Transcription factor-IN-1 (Compound 4e) is an inhibitor for transcription factor. Transcription factor-IN-1 exhibits anticonvulsant activity by antagonism with pentylenetetrazole (PTZ) (ED50 =34.5 mg/kg). Transcription factor-IN-1 exhibits antidepressant effects in rat models.
    Transcription factor-IN-1
  • HY-161909
    USP30-I-1 2511541-78-7
    USP30-I-1 is a selective inhibitor of USP30 with an IC50 value of 94 nM. USP30-I-1 can be used in the research of diseases with impaired mitophagy by targeting USP30.
    USP30-I-1
  • HY-161911
    Necroptosis-IN-5
    Necroptosis-IN-5 (Compound 26) is an orally active necroptosis inhibitor. Necroptosis-IN-5 also exhibits potent inhibitory activity against receptor-interacting protein kinase 1 (RIPK1). Necroptosis-IN-5 can be used to study necroptosis-related inflammatory diseases, neurodegenerative diseases, and cancers.
    Necroptosis-IN-5
  • HY-161914
    P2X3 antagonist 39
    P2X3 antagonist 39 (compound 26a) is a selective P2X3 receptor antagonist with an IC50 value of 54.9 nM. P2X3 antagonist 39 can be used in the study of neuropathic pain model.
    P2X3 antagonist 39
  • HY-161918
    SARM1-IN-3 3046146-15-7
    SARM1-IN-3 (Example 30) is a SARM1 inhibitor. SARM1-IN-3 can be used in the study of chemotherapy induced peripheral neuropathy (CIPN).
    SARM1-IN-3
  • HY-161925
    sTGFBR3 antagonist 1
    sTGFBR3 antagonist 1 (Compound p24) is an antagonist for soluble transforming growth factor beta receptor 3 (sTGFBR3), thus activates TGF-β signaling pathway, and inhibits IκBα/NF-κB signaling pathway. sTGFBR3 antagonist 1 inhibits NO-release in LPS (HY-D1056) -induced BV2 cells with an IC50 of 0.52 μM. sTGFBR3 antagonist 1 exhibits anti-inflammatory and neuroprotective activities with blood brain barrier (BBB) permeability. sTGFBR3 antagonist 1 can be used in Alzheimer’s Disease research.
    sTGFBR3 antagonist 1
  • HY-161943
    NEU3-IN-1
    NEU3-IN-1 (compound 963) is a NEU3 inhibitor (Ki: 0.12 μM; IC50: 0.31 μM) based on the 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA) scaffold and is a C9 biphenylcarbamate derivative. NEU is a human neuraminidase with 4 isozymes; NEU3-IN-1 is an important tool for studying the function of NEU3 isozymes; its amide and triazole linker analogs are selective for NEU1 and NEU4 isozymes, respectively.
    NEU3-IN-1
  • HY-161953
    O-GlcNAcase-IN-2
    O-GlcNAcase-IN-2 (compound 81) is an orally effective, blood-brain barrier-permeable OGA inhibitor (IC50=4.93 nM). O-GlcNAcase-IN-2 can increase the O-GlcNAcylation level of proteins and phosphorylation of tau (p-Ser199, p-Thr205 and p-Ser396) in the OA-damaged SH-SY5Y cell model. O-GlcNAcase-IN-2 can also improve cognitive impairment in APP/PS1 mice and has potential anti-Alzheimer's disease (AD) effects.
    O-GlcNAcase-IN-2
  • HY-161992
    Nrf2 activator-11
    Nrf2 activator-11 (compound M11) is a Nrf2 activator with blood-brain permeability. Nrf2 activator-11 has anti-oxidation, anti-inflammation, anti-ferroptosis and anti-apoptosis. Nrf2 activator-11 can be used to study cerebral  ischemia-reperfusion (CI/R) injury models.
    Nrf2 activator-11
  • HY-162005
    AChE-IN-48
    AChE-IN-48 (compound 16) is AChE inhibitor ,with the IC50 of 41.87 μM. AChE-IN-48 can be used for Alzheimer's disease study.
    AChE-IN-48
  • HY-162020
    SB1617
    SB1617 is a neuroinflammation-modulating agent, and has neuroprotective effect by reducing pathogenic tau levels through microglia-mediated anti-inflammatory activity.
    SB1617
  • HY-162027
    PB118
    PB118 is a potent inhibitor of HDAC6 that plays an important role in the pathophysiology of Alzheimer's disease.
    PB118
Cat. No. Product Name / Synonyms Application Reactivity